diabetes drug

Ozempic and Wegovy Linked to Severe Vision Loss in New Study

The popular diabetes and weight loss medications Ozempic and Wegovy, both containing the active ingredient semaglutide, have been hailed as revolutionary treatments in recent years. However, a new semaglutide study published this month in the medical journal JAMA Ophthalmology has uncovered a troubling connection between these popular drugs and a debilitating eye condition called nonarteritic […]

Ozempic and Wegovy Linked to Severe Vision Loss in New Study Read More »

Study Finds Side Effects of GLP-1 Drugs Could Cause Bone Density Loss

A troubling new study has uncovered another potential side effect of Ozempic, Wegovy, Mounjaro, and other popular glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. According to researchers, these in-demand treatments may be linked to a significant reduction in bone mineral density (BMD), potentially putting users at risk of osteoporosis and fractures. As the medical community

Study Finds Side Effects of GLP-1 Drugs Could Cause Bone Density Loss Read More »

Ozempic Lawsuit: Iowa Man Seeks Justice for Devastating Health Problems

An Iowa man has taken legal action against the manufacturers of Ozempic, a widely prescribed diabetes drug. In a product liability lawsuit filed last week in the U.S. District Court for the Northern District of Iowa, plaintiff Shawn Derrick alleges that Novo Nordisk and its subsidiaries failed to provide adequate warnings about the health risks

Ozempic Lawsuit: Iowa Man Seeks Justice for Devastating Health Problems Read More »

Ozempic

Did You Suffer Stomach Paralysis After Ozempic injections? Ozempic has allegedly been linked to the development of gallstones, cholecystitis, gallbladder disease, and gastroparesis, a condition where the stomach becomes paralyzed. Individuals who have taken Ozempic have reported severe stomach problems, including hospitalizations, surgery and severe health issues leading to Ozempic lawsuits against the manufacturer, Novo

Ozempic Read More »

Scroll to Top